BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10322156)

  • 1. Mimotopes of cytolytic T lymphocytes in cancer immunotherapy.
    Chen L
    Curr Opin Immunol; 1999 Apr; 11(2):219-22. PubMed ID: 10322156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
    Blake J; Johnston JV; Hellström KE; Marquardt H; Chen L
    J Exp Med; 1996 Jul; 184(1):121-30. PubMed ID: 8691125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
    Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
    Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer.
    Araki K; Noguchi Y; Hirouchi T; Yoshikawa E; Kataoka S; Silverni L; Miyazawa H; Kuzuhara H; Suzuki C; Shimada Y; Hamasato S; Maeda N; Shimamura Y; Ogawa Y; Ohtsuki Y; Fujimoto S
    Int J Oncol; 2000 Dec; 17(6):1107-18. PubMed ID: 11078795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
    Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
    Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
    J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
    Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
    Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo.
    Webb AI; Dunstone MA; Williamson NA; Price JD; de Kauwe A; Chen W; Oakley A; Perlmutter P; McCluskey J; Aguilar MI; Rossjohn J; Purcell AW
    J Immunol; 2005 Sep; 175(6):3810-8. PubMed ID: 16148127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.
    Wu J; Wei J; Meng K; Chen J; Gao W; Zhang J; Xu Z; Miao Y
    Immunopharmacol Immunotoxicol; 2009; 31(3):468-76. PubMed ID: 19555216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.